This site is intended for health professionals only

Published on 26 November 2008

Share this story:
Twitter
LinkedIn

New drug approved for HIV treatment

teaser

Pfizer’s anti-HIV drug Selzentry (maraviroc) has been granted full (traditional) approval for adults with CCR5-tropic HIV-1 by the US Food and Drug Administration (FDA).

The treatment is part of a new class of drugs styled CCR5 antagonists, which are intended for use after a patient is diagnosed with the disease, also known as “R5 virus”.

Selzentry stops the virus getting into CD4 T-cells that express the CCR5 co-receptor rather than fighting it inside the cell, as do all other classes of oral HIV medicines.

W David Hardy, from Cedars-Sinai Medical Centre, said: “New, effective and well-tolerated treatment options are critical for treatment-experienced persons living with HIV infection.

“Selzentry, the first oral entry inhibitor, has proven to be an effective and well-tolerated treatment option for treatment-experienced patients whose HIV has become resistant to other treatments, but remains susceptible to this new class of medications.”

Accelerated conditional approval is granted to medicines that provide a meaningful therapeutic advantage for serious or life-threatening diseases.

Said Dr Howard Mayer, Pfizer’s executive director and development team leader for HIV/AIDS: “Selzentry has been on a long journey, from its initial discovery by Pfizer scientists in 2000 to this full FDA approval.”

Copyright Press Association 2008

Selzentry



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn